Home
About
Overview
Sharing Data
ORCID
Help
History (15)
Principal Investigator
Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial.
Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up.
Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer.
What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer?
See All 15 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer?
What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer? Ther Adv Med Oncol. 2023; 15:17588359231198446.
View in:
PubMed
authors with profiles
Jessica Donington
James Dolezal
Everett Vokes
Marina Chiara Garassino
Christine Bestvina
Robert Cameron